Blood News and Research

RSS

EKOS receives $2.7M grant to develop product for treatment of ICH

EKOS Corporation announced today that they received a $2.7 million grant from the National Institutes of Health for the development of a product to provide therapy for intracerebral hemorrhagic stroke.

7 Jun 2010

UBMD selects Allscripts EHR solution to help its physicians enhance quality of patient care

Allscripts announced today that UBMD has selected the Allscripts Electronic Health Record solution to help its 450 physicians enhance the quality of patient care, improve patient communications, and better manage the cost of care delivery.

7 Jun 2010

Angiochem presents positive Phase 1/2 clinical data of ANG1005 for brain cancer at ASCO 2010

Angiochem, Inc., a clinical-stage biotechnology company developing drugs that are uniquely capable of crossing the blood-brain barrier (BBB) through LRP-1 targeting, announced today that complete phase 1/2 clinical data in two clinical studies of its lead oncology program, ANG1005, for the treatment of brain cancers, including glioblastoma (GBM) and brain metastases, were presented at the 2010 American Society for Clinical Oncology (ASCO) Annual Meeting, June 4-8, in Chicago, IL.

7 Jun 2010

Alnylam presents interim data from ALN-VSP02 Phase I trial for liver cancer at ASCO 2010

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today preliminary clinical data from its ongoing Phase I trial with ALN-VSP, a systemically delivered RNAi therapeutic for the treatment of advanced solid tumors with liver involvement.

7 Jun 2010

Guardian Home Care Holdings, Cardiocom provide home telehealth technology to patients with chronic illnesses

Guardian Home Care Holdings, Inc., a leading provider of home care and hospice services, announced it has entered into a business relationship with Cardiocom to provide advanced home telehealth technology to patients with chronic illnesses. Cardiocom is a developer, manufacturer and clinical service provider of award-winning telehealth solutions.

7 Jun 2010

FDA approves 45mm GORE TAG Thoracic Endoprosthesis device

W. L. Gore & Associates (Gore) today announced that it has received approval from the U.S. Food and Drug Administration (FDA) to market a 45 mm diameter version of the GORE® TAG® Thoracic Endoprosthesis for treatment of aneurysms of the descending thoracic aorta. The larger diameter device allows treatment of TAAs with proximal and distal neck diameters ranging from 37 - 42 mm and is now available for commercial use in the U.S.

7 Jun 2010

SunTech Medical named Rookie Vendor of the Year

SunTech Medical was named 'Rookie Vendor of the Year' at Medline Industries, Inc.'s annual meeting for their HealthCare sales division in Montgomery, Texas. SunTech supplies Medline with the 247 Diagnostic Station, a blood pressure device that can also serve as a vital signs monitor, which Medline distributes to nursing homes and hospitals across the United States.

7 Jun 2010

Ranibizumab improves vision in patients with visual impairment due to DME: RESTORE study

Results from a new major diabetes eye health study may have the potential to change the way vision loss due to diabetic macular edema, a serious and devastating complication of diabetes, is treated. One year results from the RESTORE study show that 37 per cent of patients treated with ranibizumab only and 43 per cent of those treated with ranibizumab plus laser therapy, had a significant improvement in visual acuity of 10 letters or more on an eye chart, compared to 16 per cent of patients treated with laser alone - the current standard treatment for visual impairment due to DME.

7 Jun 2010

Chronix's serum DNA assays have potential to detect early stage breast cancer, prostate cancer

Chronix Biomedical today reported new data further demonstrating that its serum DNA blood tests have the potential to accurately detect early stage breast cancer and prostate cancer. Chronix's proprietary technology identifies disease-specific genetic fingerprints based on circulating DNA fragments that are released into the bloodstream by damaged and dying (apoptotic) cells.

7 Jun 2010

Genentech reports results from Phase III study of Avastin in women with advanced ovarian cancer

Genentech, Inc., a wholly owned member of the Roche Group, today announced results from a Phase III study of Avastin (bevacizumab) that showed women with previously untreated advanced ovarian cancer who received Avastin in combination with chemotherapy, followed by the continuation of Avastin alone, had a 39 percent improvement in the likelihood of living longer without the disease worsening (progression-free survival or PFS) compared to chemotherapy alone.

7 Jun 2010

Novartis' Afinitor decreases size of SEGAs associated with tuberous sclerosis

Novartis Pharmaceuticals Corporation announced today that results from a Phase II study show Afinitor® (everolimus) tablets is the first medication in a clinical trial to decrease the size of subependymal giant cell astrocytomas (SEGAs), benign brain tumors associated with tuberous sclerosis (TS). In this study of 28 patients presented today at the 46th American Society of Clinical Oncology (ASCO) annual meeting in Chicago, 75% of patients experienced a reduction of 30% or greater in the size of their brain tumors from baseline to six months (p<0.001).

7 Jun 2010

Thesis examines infections caused by Anaplasma phagocytophilum in lambs

Erik Georg Granquist's thesis examines infections caused by the bacterium Anaplasma phagocytophilum in lambs. This bacterium is the cause of the disease tick-borne fever in ruminants and granulocytic anaplasmosis in humans. The bacterium is transmitted by ticks and is the indirect cause of considerable animal welfare problems and financial losses in Norwegian sheep farming.

7 Jun 2010

AMG 386 demonstrates antitumor activity in Phase 2 trial involving patients with recurrent ovarian cancer

Amgen today announced that AMG 386, combined with paclitaxel, demonstrated antitumor activity in a randomized Phase 2 trial involving 161 patients with recurrent ovarian cancer. The results are being presented for the first time in an oral presentation at the 2010 American Society of Clinical Oncology Annual Meeting.

7 Jun 2010

TransMedia to publicize Protectus Automatic, Self-Sheathing Safety Syringe

Protectus Medical Devices, Inc. has retained TransMedia Group to publicize the first automatic, self-sheathing syringe designed to eliminate accidental needle stick injuries that claim the lives of medical professionals and force the industry to spend billions of dollars testing and treating victims for blood borne diseases.

7 Jun 2010

Bevacizumab extends progression-free survival in women with advanced ovarian cancer

Newly reported results from a major clinical trial show that adding bevacizumab (Avastin) to standard frontline chemotherapy for women with advanced ovarian cancer and then continuing a maintenance dose of the drug afterwards significantly extends progression-free survival. Women receiving the new treatment regimen saw no worsening of their disease for 14.1 months, compared to 10.3 months for women receiving standard therapy.

7 Jun 2010

Chemotherapy delivered directly into liver blood vessels increases progression-free survival in melanoma patients

Patients undergoing treatment for melanoma that has spread to the liver may respond well to chemotherapy delivered directly into the liver's blood vessels, according to a study sponsored by the National Cancer Institute and Delcath Systems Inc., and led by James F. Pingpank, M.D., associate professor of surgery, University of Pittsburgh School of Medicine, and surgical oncologist with UPMC Cancer Centers. The results will be disclosed in an oral presentation on June 5 in Chicago at the 46th annual meeting of the American Society of Clinical Oncology (ASCO).

7 Jun 2010

The Iacocca Family Foundation and Kineta partner to develop Type 1 diabetes mellitus drug

Kineta, Inc. joined with The Iacocca Family Foundation today to announce a new investment partnership to speed development of Kineta's preclinical autoimmune drug candidate - ShK-186 - and its multiple applications to treat Type 1 diabetes mellitus.

7 Jun 2010

Eisai's eribulin mesylate improves median OS compared with TPC in pre-treated metastatic breast cancer patients

Results of a Phase III study presented today at the American Society of Clinical Oncology (ASCO) Annual Meeting showed that Eisai's eribulin mesylate significantly improved median overall survival (OS) compared with Treatment of Physician's Choice (TPC) in heavily pre-treated metastatic breast cancer patients.

7 Jun 2010

Ipilimumab extends survival of metastatic melanoma patients: Study

A therapy that multiplies the effect of a natural disease-fighting antibody has extended the lives of patients with metastatic melanoma in a large, international clinical trial. The study's researchers will report their findings simultaneously at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago and in the New England Journal of Medicine.

7 Jun 2010

Phase I study results of Pharmacyclics' PCI-32765 Btk inhibitor for B cell NHL presented at ASCO

Pharmacyclics, Inc. today announced results from a Phase I study of its novel orally administered Bruton's tyrosine kinase (Btk) inhibitor, PCI-32765, in patients with relapsed or refractory B cell non-Hodgkin's lymphoma (NHL) including chronic lymphocytic leukemia (CLL) and Waldenstroms Macroglobulinemia (WM). These data are being presented at the American Society of Clinical Oncology (ASCO) Annual Meeting taking place this week in Chicago, IL.

7 Jun 2010

Blood News and Research

EKOS receives $2.7M grant to develop product for treatment of ICH

UBMD selects Allscripts EHR solution to help its physicians enhance quality of patient care

Angiochem presents positive Phase 1/2 clinical data of ANG1005 for brain cancer at ASCO 2010

Alnylam presents interim data from ALN-VSP02 Phase I trial for liver cancer at ASCO 2010

Guardian Home Care Holdings, Cardiocom provide home telehealth technology to patients with chronic illnesses

FDA approves 45mm GORE TAG Thoracic Endoprosthesis device

SunTech Medical named Rookie Vendor of the Year

Ranibizumab improves vision in patients with visual impairment due to DME: RESTORE study

Chronix's serum DNA assays have potential to detect early stage breast cancer, prostate cancer

Genentech reports results from Phase III study of Avastin in women with advanced ovarian cancer

Novartis' Afinitor decreases size of SEGAs associated with tuberous sclerosis

Thesis examines infections caused by Anaplasma phagocytophilum in lambs

AMG 386 demonstrates antitumor activity in Phase 2 trial involving patients with recurrent ovarian cancer

TransMedia to publicize Protectus Automatic, Self-Sheathing Safety Syringe

Bevacizumab extends progression-free survival in women with advanced ovarian cancer

Chemotherapy delivered directly into liver blood vessels increases progression-free survival in melanoma patients

The Iacocca Family Foundation and Kineta partner to develop Type 1 diabetes mellitus drug

Eisai's eribulin mesylate improves median OS compared with TPC in pre-treated metastatic breast cancer patients

Ipilimumab extends survival of metastatic melanoma patients: Study

Phase I study results of Pharmacyclics' PCI-32765 Btk inhibitor for B cell NHL presented at ASCO

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News